RARE vs XERS · rev $350.0M vs rev $175.2M
Ultragenyx (RARE) versus Xeris Pharmaceuticals Inc (XERS) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Xeris Pharmaceuticals Inc (XERS) is a biotechnology company listed on US.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported XERS revenue for 2026-06-30 was $175.2M. Net income was -$28.9M. XERS currently screens at market cap $760.7M.
RARE currently screens at market cap $2.79B. XERS currently screens at market cap $760.7M.
Not investment advice. Open the RARE and XERS stock pages for the full models.
Not investment advice.